IL262103B - mdm2 protein assemblies - Google Patents
mdm2 protein assembliesInfo
- Publication number
- IL262103B IL262103B IL262103A IL26210318A IL262103B IL 262103 B IL262103 B IL 262103B IL 262103 A IL262103 A IL 262103A IL 26210318 A IL26210318 A IL 26210318A IL 262103 B IL262103 B IL 262103B
- Authority
- IL
- Israel
- Prior art keywords
- mdm2 protein
- protein degraders
- degraders
- mdm2
- protein
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title 1
- 239000001064 degrader Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318974P | 2016-04-06 | 2016-04-06 | |
| US201662393874P | 2016-09-13 | 2016-09-13 | |
| US201662409571P | 2016-10-18 | 2016-10-18 | |
| PCT/US2017/026274 WO2017176957A1 (en) | 2016-04-06 | 2017-04-06 | Mdm2 protein degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL262103A IL262103A (en) | 2018-11-29 |
| IL262103B true IL262103B (en) | 2021-05-31 |
Family
ID=58549316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL262103A IL262103B (en) | 2016-04-06 | 2018-10-03 | mdm2 protein assemblies |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192898B2 (enExample) |
| EP (1) | EP3440066B1 (enExample) |
| JP (2) | JP7037500B2 (enExample) |
| KR (1) | KR102387316B1 (enExample) |
| CN (2) | CN113788818A (enExample) |
| AU (1) | AU2017246452C1 (enExample) |
| IL (1) | IL262103B (enExample) |
| MX (1) | MX2018012174A (enExample) |
| RU (2) | RU2021102253A (enExample) |
| SG (1) | SG11201808728QA (enExample) |
| UA (1) | UA123786C2 (enExample) |
| WO (1) | WO2017176957A1 (enExample) |
| ZA (1) | ZA201806968B (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3440066B1 (en) * | 2016-04-06 | 2022-11-30 | The Regents of The University of Michigan | Mdm2 protein degraders |
| WO2017185036A1 (en) | 2016-04-22 | 2017-10-26 | Dana Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| JP6957620B2 (ja) | 2016-12-01 | 2021-11-02 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| ES2992913T3 (en) | 2017-07-10 | 2024-12-19 | Celgene Corp | 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| EP3679028A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| CA3076613A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CN110357889B (zh) | 2018-04-09 | 2022-03-15 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| CN111989322B (zh) | 2018-04-23 | 2024-04-02 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| EP3787747A4 (en) * | 2018-04-30 | 2022-01-12 | Dana-Farber Cancer Institute, Inc. | POLYBROMO-1 (PBRM1) SMALL MOLECULE DEGRADATION PRODUCTS |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN108864113B (zh) * | 2018-08-03 | 2021-08-13 | 南方科技大学 | 一种mdm2-hdac双靶点抑制剂、药物组合物及其制备和用途 |
| US12268665B2 (en) * | 2018-08-08 | 2025-04-08 | Ascentage Pharma (Suzhou) Co., Ltd | Combination of immunotherapies with MDM2 inhibitors |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| BR112021003098A2 (pt) | 2018-08-22 | 2021-05-11 | Cullgen (Shanghai), Inc. | compostos de degradação de receptor de tropomiosina quinase (trk) e métodos de uso |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| CN110963958B (zh) * | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| CA3112591A1 (en) | 2018-10-08 | 2020-04-16 | The Regents Of The University Of Michigan | Small molecule mdm2 protein degraders |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| US10844039B2 (en) | 2018-11-13 | 2020-11-24 | Biotheryx, Inc. | Substituted isoindolinones |
| TWI750539B (zh) * | 2018-11-23 | 2021-12-21 | 大陸商蘇州亞盛藥業有限公司 | 新穎藥物組成物及其用途 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| KR20250167680A (ko) | 2018-11-30 | 2025-12-01 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| AU2019399772B2 (en) | 2018-12-14 | 2021-11-04 | Ascentage Pharma (Suzhou) Co., Ltd. | A compound for treating osteoarthritis |
| CN113453679B (zh) | 2018-12-20 | 2025-07-08 | C4医药公司 | 靶向蛋白降解 |
| WO2020160295A1 (en) | 2019-01-30 | 2020-08-06 | Montelino Therapeutics, Llc | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US11547759B2 (en) | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| TWI875749B (zh) | 2019-04-05 | 2025-03-11 | 美商凱麥拉醫療公司 | Stat降解劑及其用途 |
| WO2020232115A1 (en) * | 2019-05-14 | 2020-11-19 | Wisconsin Alumni Research Foundation | Bifunctional nutlin-lenalidomide derivatives ((4,5-dihydro-1h-imidazole-1-carbonyl)piperazin-1-yl-[linker]-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives) as mdm2 degraders and mdm2-p53 inhibitors for use in cancer therapy |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| CA3144805A1 (en) | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP3814358B1 (en) * | 2019-07-11 | 2025-09-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing 2-indolinospirone compounds and intermediates thereof |
| CN119954801A (zh) | 2019-07-17 | 2025-05-09 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| NZ787624A (en) | 2019-10-17 | 2025-07-25 | Arvinas Operations Inc | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| CN112745298B (zh) * | 2019-10-30 | 2024-04-09 | 中国科学院上海药物研究所 | 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途 |
| US11548870B2 (en) | 2019-11-19 | 2023-01-10 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of helios protein |
| AU2020407200A1 (en) | 2019-12-17 | 2022-07-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11850239B2 (en) | 2019-12-19 | 2023-12-26 | Ascentage Pharma (Suzhou) Co., Ltd. | MDM2 inhibitor and a platinum compound for cancer treatment |
| KR20220151160A (ko) | 2019-12-23 | 2022-11-14 | 카이메라 쎄라퓨틱스 인코포레이티드 | Smarca 분해제 및 이의 용도 |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| TWI777380B (zh) * | 2020-01-23 | 2022-09-11 | 大陸商蘇州亞盛藥業有限公司 | 2-吲哚啉螺環酮類化合物之結晶形式 |
| US12410171B2 (en) | 2020-02-26 | 2025-09-09 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| CN115380026B (zh) * | 2020-03-17 | 2023-11-07 | 南京明德新药研发有限公司 | 蛋白降解调节剂与其使用方法 |
| EP4121043A4 (en) * | 2020-03-19 | 2024-07-24 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| CN113509557A (zh) * | 2020-04-09 | 2021-10-19 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| JP2023534528A (ja) * | 2020-07-20 | 2023-08-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED DEGRADATION OF RET |
| CA3181715A1 (en) | 2020-08-27 | 2022-03-03 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US20240024494A1 (en) * | 2020-09-11 | 2024-01-25 | Shanghai Mewsgen Biotechnology Co., Ltd | Small-molecule conjugate and use thereof |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| PH12023500015A1 (en) | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN114853731A (zh) * | 2021-02-04 | 2022-08-05 | 上海长森药业有限公司 | 一种双功能mdm2蛋白降解剂，及其制备方法、药物组合物和应用 |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| HRP20250796T1 (hr) | 2021-04-06 | 2025-08-29 | Bristol-Myers Squibb Company | Piridinil supstituirani oksoizoindolinski spojevi |
| PE20240639A1 (es) | 2021-04-16 | 2024-04-04 | Arvinas Operations Inc | Moduladores de la proteolisis bcl6 y metodos de uso asociados |
| CN117580592A (zh) | 2021-05-05 | 2024-02-20 | 渤健马萨诸塞州股份有限公司 | 用于靶向布鲁顿酪氨酸激酶降解的化合物 |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US20240343733A1 (en) | 2021-07-07 | 2024-10-17 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
| EP4366834A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
| IL309666A (en) | 2021-07-09 | 2024-02-01 | Plexium Inc | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| US11981672B2 (en) | 2021-09-13 | 2024-05-14 | Montelino Therapeutics Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| EP4402143A1 (en) | 2021-09-13 | 2024-07-24 | Astrazeneca AB | Spirocyclic compounds |
| WO2023049790A2 (en) * | 2021-09-22 | 2023-03-30 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| AR127505A1 (es) | 2021-10-29 | 2024-01-31 | Kymera Therapeutics Inc | Degradadores irak-4 y síntesis de los mismos |
| US20230233546A1 (en) * | 2021-12-15 | 2023-07-27 | Kymera Therapeutics, Inc. | Methods of treating cancer |
| CN113979999B (zh) * | 2021-12-23 | 2022-05-20 | 北京鑫开元医药科技有限公司 | 靶向泛素化降解bcr-abl激酶的化合物及其制备方法、组合物和用途 |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| WO2023230059A1 (en) * | 2022-05-24 | 2023-11-30 | Newave Pharmaceutical Inc. | Mdm2 degrader |
| WO2024006776A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and medical use thereof |
| KR20250041622A (ko) | 2022-06-27 | 2025-03-25 | 릴레이 테라퓨틱스, 인크. | 에스트로겐 수용체 알파 분해제 및 그의 용도 |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024078370A1 (zh) * | 2022-10-13 | 2024-04-18 | 中国科学院上海药物研究所 | 具有取代苯基螺[吲哚啉-3,3'-吡咯烷]结构的小分子化合物 |
| WO2024097948A1 (en) | 2022-11-04 | 2024-05-10 | Roivant Discovery, Inc. | Degraders of mdm2 and uses thereof |
| WO2024148257A1 (en) * | 2023-01-05 | 2024-07-11 | The Wistar Institute Of Anatomy And Biology | Mdm2 targeting protacs |
| WO2024187066A1 (en) * | 2023-03-08 | 2024-09-12 | Regents Of The University Of Michigan | Compounds and compositions as cbp/p300 degraders and uses thereof |
| WO2024197219A1 (en) * | 2023-03-22 | 2024-09-26 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| KR20240166948A (ko) * | 2023-05-18 | 2024-11-26 | 아주대학교산학협력단 | 골 분화 유도 가능한 신규 화합물 |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| AU716490B2 (en) | 1996-09-13 | 2000-02-24 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compounds and pharmaceutical use thereof |
| US6831155B2 (en) | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| PL370909A1 (en) | 2001-12-18 | 2005-05-30 | F.Hoffmann-La Roche Ag | Cis-imidazolines as mdm2 inhibitors |
| ES2301717T3 (es) | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores. |
| US8146941B2 (en) * | 2002-05-17 | 2012-04-03 | Steins Karl M | Collapsible trailer |
| WO2003106384A2 (en) | 2002-06-01 | 2003-12-24 | Johns Hopkins University | Novel boronic chalcone derivatives and uses thereof |
| US20040171035A1 (en) | 2002-11-08 | 2004-09-02 | Irm Llc | Methods and compositions for modulating P53 transcription factor |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| CA2514374A1 (en) | 2003-02-13 | 2004-09-02 | Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services | Deazaflavin compounds and methods of use thereof |
| US6916833B2 (en) | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| US7829742B2 (en) | 2003-12-22 | 2010-11-09 | Johns Hopkins University | Boronic acid aryl analogs |
| WO2005097820A1 (en) | 2004-04-06 | 2005-10-20 | Korea Research Institute Of Bioscience And Biotechnology | Peptides for inhibiting mdm2 function |
| JP4814228B2 (ja) | 2004-05-18 | 2011-11-16 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ｃｉｓ−イミダゾリン |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| CN101023074B (zh) | 2004-09-22 | 2012-10-10 | 詹森药业有限公司 | Mdm2及p53间相互作用的抑制剂 |
| WO2006091646A2 (en) | 2005-02-22 | 2006-08-31 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| US7759383B2 (en) | 2005-02-22 | 2010-07-20 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| JP4955646B2 (ja) | 2005-03-16 | 2012-06-20 | エフ．ホフマン−ラ ロシュ アーゲー | シス−２，４，５−トリアリール−イミダゾリン及びそれらの抗癌薬としての使用 |
| TWI447120B (zh) | 2005-05-30 | 2014-08-01 | Mitsubishi Tanabe Pharma Corp | 噻吩并三唑并苯二氮呯化合物、其醫藥上之用途 |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2007107543A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| CN101528223B (zh) * | 2006-08-30 | 2013-05-01 | 密执安州立大学董事会 | Mdm2的新型小分子抑制剂和其用途 |
| US7737174B2 (en) | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| AU2007332493A1 (en) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | Imidazothiazole derivatives |
| KR101444489B1 (ko) | 2007-02-01 | 2014-09-24 | 리스버로직스 코퍼레이션 | 심혈관 질환을 예방 및 치료하기 위한 화합물 |
| WO2008106507A2 (en) | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
| KR20090122403A (ko) | 2007-03-29 | 2009-11-27 | 노파르티스 아게 | 증식성 질환의 치료를 위한 3-이미다졸릴-인돌 |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
| CA2694646C (en) * | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| CA2699707C (en) | 2007-09-21 | 2016-05-17 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between mdm2 and p53 |
| JP5478262B2 (ja) | 2007-12-28 | 2014-04-23 | 田辺三菱製薬株式会社 | 抗癌剤 |
| WO2009151069A1 (ja) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| PT2346837E (pt) | 2008-06-26 | 2015-04-02 | Resverlogix Corp | Métodos de preparação de derivados de quinazolinona |
| EP2421533B1 (en) | 2009-04-22 | 2018-10-17 | Resverlogix Corp. | Novel anti-inflammatory agents |
| DE102009051823A1 (de) | 2009-11-04 | 2011-05-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Einkristallines Schweißen von direktional verfestigten Werkstoffen |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US9102677B2 (en) | 2009-11-05 | 2015-08-11 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| JP2013510860A (ja) | 2009-11-12 | 2013-03-28 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
| US20110118283A1 (en) | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| CN104311562B (zh) | 2010-05-14 | 2017-07-04 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法 |
| US20130252331A1 (en) | 2010-05-14 | 2013-09-26 | James Elliott Bradner | Compositions and methods for modulating metabolism |
| EP2569434B1 (en) | 2010-05-14 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia and related disorders |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| EP2585465B1 (en) | 2010-06-22 | 2014-11-12 | GlaxoSmithKline LLC | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| UY33725A (es) | 2010-11-12 | 2012-06-29 | Sanofi Sa | Antagonistas de mdm2 de espiro-oxindol |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| RU2612534C2 (ru) * | 2011-03-10 | 2017-03-09 | Дайити Санкио Компани, Лимитед | Диспиропирролидиновые производные |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| MX346375B (es) * | 2011-05-11 | 2017-03-16 | Univ Michigan Regents | Antagonistas de espiro-oxindol de mdm2. |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20130245089A1 (en) | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| WO2013155695A1 (en) | 2012-04-20 | 2013-10-24 | Abbott Laboratories | Isoindolone derivatives |
| CN104718201A (zh) | 2012-06-12 | 2015-06-17 | 艾伯维公司 | 吡啶酮和哒嗪酮衍生物 |
| MX368703B (es) * | 2013-02-28 | 2019-10-11 | Amgen Inc | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. |
| AU2014249192B2 (en) * | 2013-03-11 | 2017-12-21 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
| CN107074861A (zh) * | 2014-02-28 | 2017-08-18 | 密执安大学评议会 | 作为bet溴结构域抑制剂的9h嘧啶并[4，5‑b]吲哚和相关类似物 |
| EP3129380B1 (en) | 2014-04-11 | 2018-11-28 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
| US20150291562A1 (en) | 2014-04-14 | 2015-10-15 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6694827B2 (ja) * | 2014-04-17 | 2020-05-20 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｍｄｍ２阻害剤及びそれを使用する治療方法 |
| JP6503386B2 (ja) | 2014-07-03 | 2019-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| WO2016028391A2 (en) * | 2014-08-18 | 2016-02-25 | Hudson Biopharma Inc. | Spiropyrrolidines as mdm2 inhibitors |
| CN107001385B (zh) | 2014-08-21 | 2020-03-13 | 勃林格殷格翰国际有限公司 | 作为mdm2-p53抑制剂的螺-[3h-吲哚-3，2’-吡咯烷]-2(1h)-酮化合物及其衍生物 |
| WO2016138332A1 (en) * | 2015-02-27 | 2016-09-01 | The Regents Of The University Of Michigan | 9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| EP3440066B1 (en) * | 2016-04-06 | 2022-11-30 | The Regents of The University of Michigan | Mdm2 protein degraders |
| EP3440082A1 (en) * | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| CA3112591A1 (en) * | 2018-10-08 | 2020-04-16 | The Regents Of The University Of Michigan | Small molecule mdm2 protein degraders |
-
2017
- 2017-04-06 EP EP17718290.4A patent/EP3440066B1/en active Active
- 2017-04-06 RU RU2021102253A patent/RU2021102253A/ru unknown
- 2017-04-06 CN CN202111145294.3A patent/CN113788818A/zh active Pending
- 2017-04-06 KR KR1020187032122A patent/KR102387316B1/ko active Active
- 2017-04-06 AU AU2017246452A patent/AU2017246452C1/en active Active
- 2017-04-06 SG SG11201808728QA patent/SG11201808728QA/en unknown
- 2017-04-06 CN CN201780034689.1A patent/CN109415336B/zh active Active
- 2017-04-06 MX MX2018012174A patent/MX2018012174A/es unknown
- 2017-04-06 UA UAA201810884A patent/UA123786C2/uk unknown
- 2017-04-06 US US16/091,541 patent/US11192898B2/en active Active
- 2017-04-06 WO PCT/US2017/026274 patent/WO2017176957A1/en not_active Ceased
- 2017-04-06 RU RU2018138735A patent/RU2743432C2/ru active
- 2017-04-06 JP JP2018552846A patent/JP7037500B2/ja active Active
-
2018
- 2018-10-03 IL IL262103A patent/IL262103B/en active IP Right Grant
- 2018-10-18 ZA ZA2018/06968A patent/ZA201806968B/en unknown
-
2021
- 2021-08-31 US US17/462,355 patent/US20220411432A1/en active Pending
-
2022
- 2022-03-04 JP JP2022033173A patent/JP2022078201A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113788818A (zh) | 2021-12-14 |
| BR112018070549A2 (pt) | 2019-02-12 |
| NZ747251A (en) | 2024-05-31 |
| AU2017246452B2 (en) | 2021-02-25 |
| CN109415336B (zh) | 2023-08-29 |
| SG11201808728QA (en) | 2018-11-29 |
| UA123786C2 (uk) | 2021-06-02 |
| CA3020275A1 (en) | 2017-10-12 |
| KR20180132125A (ko) | 2018-12-11 |
| US20190127387A1 (en) | 2019-05-02 |
| KR102387316B1 (ko) | 2022-04-15 |
| MX2018012174A (es) | 2019-07-08 |
| CN109415336A (zh) | 2019-03-01 |
| JP2022078201A (ja) | 2022-05-24 |
| WO2017176957A1 (en) | 2017-10-12 |
| RU2021102253A (ru) | 2021-03-03 |
| AU2017246452A1 (en) | 2018-11-08 |
| US20220411432A1 (en) | 2022-12-29 |
| EP3440066B1 (en) | 2022-11-30 |
| EP3440066A1 (en) | 2019-02-13 |
| AU2017246452C1 (en) | 2021-06-03 |
| ZA201806968B (en) | 2020-02-26 |
| JP2019510798A (ja) | 2019-04-18 |
| RU2018138735A3 (enExample) | 2020-05-12 |
| WO2017176957A8 (en) | 2018-11-08 |
| RU2743432C2 (ru) | 2021-02-18 |
| JP7037500B2 (ja) | 2022-03-16 |
| RU2018138735A (ru) | 2020-05-12 |
| US11192898B2 (en) | 2021-12-07 |
| IL262103A (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201806968B (en) | Mdm2 protein degraders | |
| ZA201806969B (en) | Bet protein degraders | |
| GB201502305D0 (en) | Protein | |
| GB201502306D0 (en) | Protein | |
| GB201509413D0 (en) | Fusion protein | |
| IL261040B (en) | Protein purification | |
| GB201415344D0 (en) | Protein | |
| GB201504691D0 (en) | Fusion protein | |
| GB201608197D0 (en) | Novel proteins | |
| PL3099791T3 (pl) | Białko | |
| GB201515745D0 (en) | Proteins | |
| GB201511787D0 (en) | Proteins | |
| GB201607534D0 (en) | Peptides | |
| GB2558968B (en) | G Proteins | |
| ZA201902689B (en) | Therapeutic protein | |
| GB201612150D0 (en) | Modified peptide | |
| GB201604468D0 (en) | Peptides | |
| GB201513033D0 (en) | Proteins | |
| ZA201801394B (en) | Fusion protein | |
| PL3099793T3 (pl) | Białko | |
| PL3469691T3 (pl) | Konfiguracja szyku halbacha | |
| GB201522610D0 (en) | Protein | |
| GB201607535D0 (en) | Peptides | |
| GB201621073D0 (en) | Bicyclic peptide | |
| GB201612665D0 (en) | Peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted |